Opinion
Video
Multidisciplinary Bispecific Care
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Amir Ali, PharmD, BCOP, FHOPA, delve into bispecific antibody treatments, focusing on strategies for patient safety and optimizing care in the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.
This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.
In this segment, Mahmoudjafari engages Ali in discussing a multidisciplinary approach to ensure patient safety during bispecific antibody treatments in both early and later phases. Ali highlights the development of guidelines for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome management and mitigation in bispecifics. He emphasizes the collaborative effort involving pharmacists, physicians, and advanced practice practitioners to create a non–product-specific guideline, ensuring consistent treatment approaches for all patients.
The discussion touches on the debate between steroids and tocilizumab for low-grade CRS, showcasing the ongoing dialogues within health care teams. Ali acknowledges the low incidence of high-grade CRS in bispecifics but emphasizes the significance of addressing even grade 1 and 2 CRS. The importance of institutional policies, standard operating procedures, and staff training to efficiently manage toxicities, including drug-specific ones like tumor flare, is underscored.
Ali mentions the availability of online resources and evolving insights, anticipating more collaborative efforts and publications in the coming months. Mahmoudjafari looks forward to further collaborations and potential publications among health care professionals to contribute to the collective knowledge on bispecific antibody treatments.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.
